Atara Biotherapeutics Inc

ATRA

$15.65

+45.7% (1 year change)

Avg closing price

Price range

Market Cap

$1.29 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$10.62 - $28.20

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

0.0x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $1.29 Billion
Enterprise Value -
Dividend Yield $0.00 (0.0%)
1 Year Return +45.7%
52-Week High $28.20
52-Week Low $10.62
Beta 1.04
Outstanding Shares 84.1 Million
Avg 30 Day Volume 829 Thousand

Valuation

P/E Ratio 0.0
PEG -
Earnings per Share $0.00
Price to Sales Ratio -
Price to Book Ratio -
Revenue to Enterprise Value -
EBIT to Enterprise Value -
Total Debt to Enterprise Value -
Debt to Equity -

Profitability

Revenue -
Gross Profit -
EBIT -
Net Income -
Profit Margin -
Quarterly Earnings Growth (YoY) -
Return on Equity -
Return on Assets -
Return on Invested Capital -

News

Mizuho Securities Stick to Their Buy Rating for Atara Biotherapeutics By Investing.com

Mizuho Securities Stick to Their Buy Rating for Atara Biotherapeutics By Investing.com

Mizuho Securities Stick to Their Buy Rating for Atara Biotherapeutics

Investing.com Investing.com, 14 days ago
Atara Biotherapeutics to Participate in Virtual 33rd Annual ROTH Conference

Atara Biotherapeutics to Participate in Virtual 33rd Annual ROTH Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transform...

Business Wire Business Wire, 4 months ago
Atara Biotherapeutics (NASDAQ:ATRA) Issues Quarterly Earnings Results, Misses Expectations By $0.22 EPS

Atara Biotherapeutics (NASDAQ:ATRA) Issues Quarterly Earnings Results, Misses Expectations By $0.22 EPS

Atara Biotherapeutics (NASDAQ:ATRA) announced its quarterly earnings data on Sunday. The biotechnology company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estim...

Transcript Daily Transcript Daily, 4 months ago